NEW YORK CITY, NY / ACCESS Newswire / November 18, 2026 / Biodesix (NASDAQ: BDSX) shareholders lost $11.31 per share -- 57.01% of the stock's value -- on November 6, 2026, after the Company reported third quarter 2026 results and cut its full-year revenue outlook. If you suffered a loss on your Biodesix investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On November 5, 2026, Biodesix reported third quarter 2026 revenue of $24 million, $3.49 million short of consensus estimates. The Company lowered its full-year 2026 revenue guidance from $108 million to $114 million down to $101 million to $103 million. The shares closed at $8.53.
Biodesix attributed the shortfall in growth in part to problems with its sales force, including staffing issues. Levi & Korsinsky is investigating whether Biodesix adequately disclosed those sales force conditions and their effect on revenue before the November 5, 2026 announcement.
Investors who purchased Biodesix shares and lost money can have their BDSX losses reviewed at no cost or reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.
Frequently Asked Questions About the BDSX Investigation
Q: What is the BDSX securities fraud investigation about?
A: A securities investigation is pending concerning Biodesix, Inc. (NASDAQ: BDSX) regarding potentially materially false or misleading statements. Shares fell approximately 57.01% after the Company disclosed third quarter 2026 revenue of $24 million and a reduced full-year 2026 revenue outlook, causing losses for shareholders.
Q: Who is conducting the BDSX investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased BDSX securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.
Q: Who is eligible to participate in the BDSX investigation?
A: Investors who purchased BDSX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do BDSX investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my BDSX shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought BDSX and sold at a loss may still participate in the investigation.
Q: What if my BDSX losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire